# A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Source: https://onco.cc/trials/nct06697184/  
OnCo record `nct06697184` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sonrotoclax, Zanubrutinib in mantle cell lymphoma, run by BeOne Medicines, now recruiting.

## Summary

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. is a phase 1/2 interventional study registered as NCT06697184 by BeOne Medicines, with 258 participants planned, started 2025-01-23 and due to reach its primary completion in 2029-11-30. Interventions recorded: Sonrotoclax, Zanubrutinib. Conditions listed: Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06697184
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies.
- Sponsor: BeOne Medicines
- Enrolled: 258

## Sources

- ClinicalTrials.gov NCT06697184: https://clinicaltrials.gov/study/NCT06697184

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct06697184.json